Lv3
330 积分 2023-08-25 加入
Cancer burden and control in China: landscape, trends and challenges
1天前
待确认
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
2个月前
已完结
Adjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoadjuvant Immunotherapy
2个月前
已完结
Revisiting neoadjuvant therapy in non-small-cell lung cancer
2个月前
已完结
Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization
2个月前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
2个月前
已完结
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
2个月前
已完结
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy
3个月前
已完结
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
3个月前
已完结
皖公网安备34019202002308
